Innovent Biologics (STU:6IB) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:6IB Innovent Biologics Inc STU:6IB
80 GF Score
Price €10.10
GF Value €11.08
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Innovent Biologics Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Innovent Biologics is: High Risk: High uncertainty with risk-return tradeoff.

Innovent Biologics  (STU:6IB) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Innovent Biologics Risk Assessment Related Terms

STU:6IB vs VRTX, REGN, ALNY: Risk Assessment Comparison

For the Biotechnology subindustry, Innovent Biologics's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovent Biologics Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovent Biologics's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's Risk Assessment falls into.


STU:6IB
80GF Score
Innovent Biologics Inc STU:6IB
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Innovent Biologics (STU:6IB) Overvalued in 2026?

Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued. The current stock price of €10.10 is trading 8.8% below its estimated GF Value™ of €11.08. GuruFocus considers Innovent Biologics to be Fairly Valued.

Key valuation signals for STU:6IB:

  • Risk Assessment:
  • GF Value™: €11.08 vs. price of €10.10 (8.8% below fair value)
  • GF Score™: 80/100 with 2 warning signs

No single metric tells the full story. See the STU:6IB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Innovent Biologics Business Description

Address 168 Dongping Street, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215123
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
80GF Score

Get the complete analysis for STU:6IB

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.10
Price
€11.08
GF Value